Novartis AG ADR (NVS)vsTactile Systems Technology Inc (TCMD)
NVS
Novartis AG ADR
$158.83
-0.25%
HEALTHCARE · Cap: $290.96B
TCMD
Tactile Systems Technology Inc
$28.20
+2.92%
HEALTHCARE · Cap: $648.27M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 16404% more annual revenue ($56.69B vs $343.52M). NVS leads profitability with a 22.5% profit margin vs 5.9%. NVS appears more attractively valued with a PEG of 4.15. TCMD earns a higher WallStSmart Score of 52/100 (C-).
NVS
Buy51
out of 100
Grade: C-
TCMD
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-70.9%
Fair Value
$92.73
Current Price
$158.83
$66.10 premium
Intrinsic value data unavailable for TCMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Revenue surging 22.8% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
5.9% margin — thin
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bull Case : TCMD
The strongest argument for TCMD centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 22.8% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : TCMD
The primary concerns for TCMD are P/E Ratio, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a value stock while TCMD is a growth play — different risk/reward profiles.
TCMD carries more volatility with a beta of 0.79 — expect wider price swings.
TCMD is growing revenue faster at 22.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
TCMD scores higher overall (52/100 vs 51/100) and 22.8% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Tactile Systems Technology Inc
HEALTHCARE · MEDICAL DEVICES · USA
Tactile Systems Technology, Inc., a medical technology company, is dedicated to the development and supply of medical devices for chronic diseases in the United States. The company is headquartered in Minneapolis, Minnesota.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?